Journal article
Comprehensive genomic and tumour immune profiling reveals potential therapeutic targets in malignant pleural mesothelioma
J Creaney, AM Patch, V Addala, SA Sneddon, K Nones, IM Dick, YCG Lee, F Newell, EJ Rouse, MM Naeini, O Kondrashova, V Lakis, A Nakas, D Waller, A Sharkey, P Mukhopadhyay, SH Kazakoff, LT Koufariotis, AL Davidson, P Ramarao-Milne Show all
Genome Medicine | BMC | Published : 2022
Abstract
Background: Malignant pleural mesothelioma (MPM) has a poor overall survival with few treatment options. Whole genome sequencing (WGS) combined with the immune features of MPM offers the prospect of identifying changes that could inform future clinical trials. Methods: We analysed somatic mutations from 229 MPM samples, including previously published data and 58 samples that had undergone WGS within this study. This was combined with RNA-seq analysis to characterize the tumour immune environment. Results: The comprehensive genome analysis identified 12 driver genes, including new candidate genes. Whole genome doubling was a frequent event that correlated with shorter survival. Mutational sig..
View full abstractGrants
Awarded by Ian Potter Foundation
Funding Acknowledgements
This work was funded by the Australian National Medical and Research Council (NHMRC) (APP1089404). NW is funded by a National Health and Medical Research Council of Australia (NHMRC) Senior Research Fellowship (APP1139071). BWR is funded by an NHMRC Practitioner Fellowship (APP1108638). VA and ALD are supported by Australian Government Research Training Program (RTP) Scholarships and QIMR Berghofer HDC PhD top up Scholarships. This work and this research was performed on QIMR Berghofer computing infrastructure supported by The Ian Potter Foundation and The John Thomas Wilson Endowment. We are grateful to the Estate of Mr Stewart Coggins for support to AMP, PM and SHK.